Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROLLEY: Cardiohelp System and Anticoagulation in Pediatric Severe Cardiac Failure
NCT06080074Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Apr 2025
- Primary completion
- Sep 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of heparin, bivalirudin in heart failure (HF), cardiogenic shock, congenital heart disease (CHD), cardiomyopathy, sponsored by Stanford University. Started Apr 2025; status: recruiting.
02
Drugs
heparinbivalirudin
03
Conditions
heart failure (HF)cardiogenic shockcongenital heart disease (CHD)cardiomyopathy
Beyond the preview
Go deeper on NCT06080074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06080074.